Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

425 ARTÍCULOS , VIENDO DEL 106 AL 120

Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease

Ozben T, Ozben S.

Clin Biochem. 2019 Oct;72:87-89. doi: 10.1016/j.clinbiochem.2019.04.001. Epub 2019 Apr 4.

Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?

De Simone A, Milelli A.

ChemMedChem. 2019 Jun 5;14(11):1067-1073. doi: 10.1002/cmdc.201900174. Epub 2019 May 2.

Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy

Tosi G, Pederzoli F, Belletti D, Vandelli MA, Forni F, Duskey JT, Ruozi B.

Prog Brain Res. 2019;245:57-88. doi: 10.1016/bs.pbr.2019.03.001. Epub 2019 Apr 2.

Monoamines and their Derivatives on GPCRs: Potential Therapy for Alzheimer's Disease

Farfán-García ED, Márquez-Gómez R, Barrón-González M, Pérez-Capistran T, Rosales-Hernández MC, Pinto-Almazán R, Soriano-Ursúa MA.

Curr Alzheimer Res. 2019;16(10):871-894. doi: 10.2174/1570159X17666190409144558.

Formaldehyde, Epigenetics, and Alzheimer's Disease

Wang F, Chen D, Wu P, Klein C, Jin C.

Chem Res Toxicol. 2019 May 20;32(5):820-830. doi: 10.1021/acs.chemrestox.9b00090. Epub 2019 Apr 19.

Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis

Manolopoulos A, Andreadis P, Malandris K, Avgerinos I, Karagiannis T, Kapogiannis D, Tsolaki M, Tsapas A, Bekiari E.

Am J Alzheimers Dis Other Demen. 2019 Aug;34(5):281-289. doi: 10.1177/1533317519843720. Epub 2019 Apr 15.

Effect of genetic polymorphisms on Alzheimer's disease treatment outcomes: an update

Sumirtanurdin R, Thalib AY, Cantona K, Abdulah R.

Clin Interv Aging. 2019 Mar 29;14:631-642. doi: 10.2147/CIA.S200109. eCollection 2019.

Biological Hallmarks of Cancer in Alzheimer's Disease

Nudelman KNH, McDonald BC, Lahiri DK, Saykin AJ.

Mol Neurobiol. 2019 Oct;56(10):7173-7187. doi: 10.1007/s12035-019-1591-5. Epub 2019 Apr 16.

Variability in the validity and reliability of outcome measures identified in a systematic review to assess treatment efficacy of cognitive enhancers for Alzheimer's Dementia

Soobiah C, Tadrous M, Knowles S, Blondal E, Ashoor HM, Ghassemi M, Khan PA, Ho J, Tricco AC, Straus SE.

PLoS One. 2019 Apr 18;14(4):e0215225. doi: 10.1371/journal.pone.0215225. eCollection 2019.

Non-conventional compounds with potential therapeutic effects against Alzheimer's disease

de Castro AA, Soares FV, Pereira AF, Polisel DA, Caetano MS, Leal DHS, da Cunha EFF, Nepovimova E, Kuca K, Ramalho TC.

Expert Rev Neurother. 2019 May;19(5):375-395. doi: 10.1080/14737175.2019.1608823. Epub 2019 Apr 29.

The Y(682)ENPTY(687) motif of APP: Progress and insights toward a targeted therapy for Alzheimer's disease patients

Matrone C, Iannuzzi F, Annunziato L.

Ageing Res Rev. 2019 Jul;52:120-128. doi: 10.1016/j.arr.2019.04.003. Epub 2019 Apr 27.

Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer's disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial

Hong YJ, Han HJ, Youn YC, Park KW, Yang DW, Kim S, Kim HJ, Kim JE, Lee JH; ODESA study (Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23 mg).

Alzheimers Res Ther. 2019 May 1;11(1):37. doi: 10.1186/s13195-019-0492-1.

Novel Therapeutic Potentials of Taxifolin for Amyloid-β-associated Neurodegenerative Diseases and Other Diseases: Recent Advances and Future Perspectives

Tanaka M, Saito S, Inoue T, Satoh-Asahara N, Ihara M.

Int J Mol Sci. 2019 Apr 30;20(9):2139. doi: 10.3390/ijms20092139.

Targeting Apolipoprotein E for Alzheimer's Disease: An Industry Perspective

Suidan GL, Ramaswamy G.

Int J Mol Sci. 2019 May 1;20(9):2161. doi: 10.3390/ijms20092161.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias